Abstract
At this moment, germline genetic testing is rarely requested in patients with prostate cancer. However, a breast cancer gene mutation is frequently detected in men with metastasized prostate cancer (mainly in BRCA2). In this paper we propose criteria for genetic testing in prostate cancer. Genetic test results may have major implications for relatives who may take appropriate measures to prevent cancer or diagnose it at an early stage. It may also have direct relevance for the treatment of the patient. It is time to set up a new workflow enabling treating physicians to order a DNA test (mainstreaming of genetic testing). It calls for close collaboration between clinical geneticists and treating physicians, and adequate education of urologists, oncologists and specialized nurses.
Translated title of the contribution | Genetic testing in patients with prostate cancer: new developments |
---|---|
Original language | Dutch |
Pages (from-to) | 30-35 |
Number of pages | 6 |
Journal | Tijdschrift voor Urologie |
Volume | 10 |
Issue number | 2-3 |
DOIs | |
Publication status | Published - 1 Mar 2020 |
Keywords
- BRCA2
- germline
- mainstreaming genetic testing
- metastatic prostate cancer